Stopping Overdoses of Fentanyl Analogues Act
- Bill Number
- S. 165
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2025-01-21: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2025-07-21T19:32:26Z
AI-Generated Summary
Purpose
The "Stopping Overdoses of Fentanyl Analogues Act" (S. 165) aims to combat the opioid crisis by classifying a wide range of fentanyl-related substances as Schedule I controlled substances under the Controlled Substances Act (CSA). Schedule I drugs are defined as having high potential for abuse, no accepted medical use, and lack of accepted safety for use under medical supervision. This targets synthetic opioids that mimic fentanyl to prevent overdoses from unregulated analogues.
Key Provisions
- Addition to Schedule I: Amends Section 202(c) of the CSA (21 U.S.C. 812(c)) by adding a new subsection (e) that lists "fentanyl-related substances" in Schedule I, unless specifically exempted or placed in another schedule.
- Definition of Fentanyl-Related Substances: Includes any material, compound, mixture, or preparation containing these substances, along with their isomers (chemical variants), esters, ethers, salts, and salts of those variants, if chemically possible.
- Structural Modifications: Defines fentanyl-related substances as those structurally similar to fentanyl through one or more changes, such as:
- Replacing the phenyl portion of the phenethyl group with any monocycle (a single-ring structure), with or without further substitutions.
- Substituting the phenethyl group with groups like alkyl (carbon chains), alkenyl (unsaturated carbon chains), alkoxyl, hydroxyl (-OH), halo (e.g., chlorine), haloalkyl, amino (-NH2), or nitro (-NO2).
- Substituting the piperidine ring (a key chemical ring in fentanyl) with similar groups.
- Replacing the aniline ring with any aromatic monocycle, with or without substitutions.
- Replacing the N-propionyl group (a specific acyl group) with another acyl group.
- Effective Date: Takes effect one day after enactment.
Significant Changes to Existing Law
- Expands the CSA's Schedule I category to cover a broad class of fentanyl analogues based on chemical structure, rather than requiring the Drug Enforcement Administration (DEA) to individually schedule each new variant. Previously, the DEA had to go through a rulemaking process for each analogue, which could be slow as new versions emerge.
- Builds on existing fentanyl controls but creates a more comprehensive, catch-all provision to address rapidly evolving synthetic opioids.
Potential Impacts
- On Government Agencies: The DEA and other law enforcement bodies will gain authority to prosecute possession, distribution, or manufacture of these substances more efficiently, potentially reducing administrative burdens from frequent rescheduling. Public health agencies like the Centers for Disease Control and Prevention (CDC) may see indirect benefits through decreased overdose rates.
- On Citizens: Could limit access to these highly dangerous substances, potentially saving lives by curbing overdoses (fentanyl analogues are often far more potent than heroin or prescription opioids). However, it may increase penalties for users, affecting those with addiction issues and requiring more focus on treatment programs.
- On International Relations: Strengthens U.S. efforts to pressure source countries (e.g., in Asia or Latin America) to curb production and export of synthetic opioids, possibly influencing bilateral agreements on drug control, but it does not directly alter trade or diplomatic policies.
Main Stakeholders Affected
- Law Enforcement and Regulators: DEA, FBI, and local police, who will enforce the new classifications.
- Public Health and Medical Professionals: Doctors, addiction treatment providers, and overdose response teams, who may need to adapt to updated drug monitoring and education efforts.
- Drug Manufacturers and Traffickers: Illicit producers and distributors of synthetic opioids, facing stricter federal penalties (e.g., up to life imprisonment for trafficking Schedule I substances).
- General Public and Vulnerable Populations: Individuals at risk of opioid addiction or accidental exposure, including first responders handling contaminated scenes.
Notable Legal, Constitutional, or Political Implications
- Legal: The broad structural definition could streamline enforcement but might invite challenges in court over vagueness (i.e., if the language is too imprecise to fairly apply), potentially requiring judicial clarification on what qualifies as "fentanyl-related."
- Constitutional: No direct conflicts apparent; aligns with Congress's authority under the Commerce Clause to regulate interstate drug trafficking. However, it could raise due process concerns if applied to substances with potential medical research value.
- Political: Represents a bipartisan response to the ongoing fentanyl epidemic (introduced by Senators from both parties), emphasizing public health over decriminalization debates. It may influence future opioid legislation by setting a precedent for proactive, category-based scheduling rather than reactive individual listings.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (7)
Sen. Ricketts, Pete [R-NE], Sen. Crapo, Mike [R-ID], Sen. Risch, James E. [R-ID], Sen. Banks, Jim [R-IN], Sen. Cruz, Ted [R-TX], Sen. Hyde-Smith, Cindy [R-MS], Sen. McConnell, Mitch [R-KY]
Recent Actions
- 2025-01-21: Read twice and referred to the Committee on the Judiciary.
- 2025-01-21: Introduced in Senate
Bill Versions
- Stopping Overdoses of Fentanyl Analogues Act — issued 2025-01-21 — PDF (3 pages)